The Genetics Podcast

Sano Genetics
  • 4.8 (43)
  • NATURAL SCIENCES
  • UPDATED BIWEEKLY
The Genetics Podcast

Exploring all things genetics. Dr Patrick Short, University of Cambridge alumnus and CEO of Sano Genetics, analyses the science, interviews the experts, and discusses the latest findings and breakthroughs in genetic research. To find out more about Sano Genetics and its mission to accelerate the future of precision medicine visit: www.sanogenetics.com

  1. 1D AGO

    EP 183: Rewriting the Rules for Ultra-Rare Diseases with Kent Rogers of EveryONE Medicines

    This week on The Genetics Podcast, Patrick is joined by Kent Rogers, Chief Executive Officer at EveryONE Medicines. They discuss Kent’s journey across every side of the desk in the drug discovery space, EveryONE Medicines’ efforts to develop antisense oligonucleotides for ultra-rare diseases, and the need to adapt regulatory models for n-of-1 therapies. Show Notes:  00:00 Intro to The Genetics Podcast 00:59 Welcome to Kent and his experiences across every side of the pharma ‘desk’ 06:00 Challenges of commercialization for ultra-rare disease therapies and the advantage of antisense oligonucleotides (ASOs)  10:28 EveryONE Medicines’ approach to regulatory bodies 12:30 Regulatory feedback and expectations from EveryONE Medicines’ platform-based approach to n-of-1 therapies 15:47 Differences in regulatory requirements for rare disease across countries  19:53 Insights from being on different sides of the drug development industry 22:40 Differences in healthcare systems across countries that can facilitate or impede drug development 26:57 Rationale behind focusing on ASOs for treating rare diseases   28:03 Building EveryONE Medicines and Kent’s approach to leadership 33:20 Lessons from Kent’s career 37:17 Closing remarks  Find out more EveryONE Medicines (https://www.eomeds.com/) Please consider rating and reviewing us on your chosen podcast listening platform!  https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

    40 min

  2. APR 10

    EP 182: Demystifying genetic counseling with Matt Burgess

    This week on The Genetics Podcast, Patrick is joined by Matt Burgess, genetic counselor, host of the Demystifying Genetics podcast, and Adjunct Professor at Bay Path University. They discuss the evolution of genetic counseling, ethical challenges in gene therapy, and Matt’s experiences with his podcast. Show Notes:  0:00 Intro to The Genetics Podcast 00:59 Welcome to Matt 02:09 Matt’s run-ins with Olivia Newton John while working at Austin Hospital in Melbourne 04:34 Matt’s background and path to genetic counseling  06:58 The evolution of the field of genetic counseling over time and the role of counselors 12:47 Matt’s work on rare disease AP-4 hereditary spastic paraplegia (AP-4-HSP) and the ethical considerations of gene therapy 20:22 Balancing the needs and expectations of individuals and families in counseling  23:06 Rebranding negative connotations of the word “counseling”    26:58 Memorable episodes from Matt’s podcast Demystifying Genetics 34:31 Differences in genetic counseling and healthcare in the US versus Australia and the UK 40:00 Matt’s current work on writing a novel, starting a company called Rosalind Genetics, and being involved in genetic education 42:47 The potential and drawbacks of AI models in the context of genetic counseling and information 46:46 Closing remarks Find out more Demystifying Genetics (https://demystifying-genetics.buzzsprout.com/) Please consider rating and reviewing us on your chosen podcast listening platform!  https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

    48 min

  3. APR 3

    EP 181: Transforming frustration into breakthroughs in gene therapy with Salvador Rico of Encoded Therapeutics

    This week on The Genetics Podcast, Patrick is joined by Salvador Rico, Chief Medical Officer at Encoded Therapeutics. They discuss Salvador’s journey into drug development, his work on gene therapy for X-linked myotubular myopathy, and fundamental challenges and exciting advances in the genetics field. Show Notes:  0:00 Intro to The Genetics Podcast 00:59 Welcome to Salvador and how he became involved in drug development 11:01 Frustrations and rewards of the genetics field 13:59 Salvador’s study on gene therapy for patients with X-linked myotubular myopathy (XLMTM) 19:46 Risk of liver issues in gene therapy trials and attempts to mitigate them 24:22 Encoded Therapeutics‘ approach to drug discovery and what motivated Salvador to join the team 27:22 Steps towards therapeutic targeting of gene regulatory elements  30:04 Advantages of different methods for drug delivery  32:31 DNA- versus RNA-based therapy   34:56 Insights from approaches in other fields, including psychiatry 36:35 Considerations for using natural history studies 40:32 Expectations and goals for Encoded Therapeutics’ current and upcoming studies 43:17 Closing remarks Find out more Encoded Therapeutics (https://encoded.com/) Please consider rating and reviewing us on your chosen podcast listening platform!  https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

    46 min

  4. MAR 27

    EP 180: From a consulting project to a biotech start-up with Leeland Ekstrom of Nashville Bio

    This week on The Genetics Podcast, Patrick is joined by Leeland Ekstrom, CEO and co-founder of Nashville Bio. They discuss how Leeland went from being a consultant on a project for Vanderbilt University to a co-founder of a start-up and the unique aspects of NashBio’s clinical and genetic database. Show Notes:  0:00 Intro to The Genetics Podcast 00:59 Welcome to Leeland and the origin story of Nashville Bio 05:13 Process of setting up NashBio’s genome resource with 250K individuals 11:52 How different pharmaceutical companies responded to NashBio’s database and its unique advantages compared to others 17:50 Key priorities for applications of the resource beyond target discovery 20:19 The process of selecting additional gaps that NashBio’s services can fill versus letting others fill them 25:02 Advantages at Vanderbilt Medical Center that facilitated the project and how it can be replicated at other centers 30:32 Immediate and long-term impacts of current NIH funding cuts on biotech and academia 36:43 NashBio’s current major focuses and future goals 39:20 Closing remarks Find out more NashBio (https://nashbio.com/) Press release: Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery (https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=b4b0c901-f8a2-4802-a4ef-b81167e24cfe)  Please consider rating and reviewing us on your chosen podcast listening platform!  https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

    41 min

  5. MAR 20

    EP 179: Redefining rare disease realities with Sharon Terry of the Genetic Alliance

    This week on The Genetics Podcast, Patrick is joined by Sharon Terry, President & CEO of Genetic Alliance. They discuss how Sharon established a layperson-led biobank, her long-term work on rare diseases and patient advocacy, and her program to bring genetic technology to patients in low- to middle-income countries. Show Notes:  0:00 Intro to The Genetics Podcast 00:59 Welcome to Sharon and a discussion of the personal experience with rare disease that started her journey 03:47 Reasons why Sharon decided to establish the first layperson-led biobank 05:34 Challenges with setting up the biobank infrastructure 07:00 Balancing financial factors in a non-profit organization  09:30 Recent patterns and future insight into rare disease drug discovery framework and regulation 15:32 Barriers to widespread collaboration and cooperation in rare disease research, and why it should be approached from a public health perspective 18:12 Background and experiences from the iHope Genetic Health program in low- to middle-income countries 24:44 Sharon’s perspective on current challenges with the Genetic Information Non-discrimination Act 28:49 Sharon’s lessons learned in her patient advocacy and policy work, and her hopes for future legislation   33:04 Sharon’s hopes for improved access to genetic testing and treatment for children in underserved communities 34:34 How Sharon learned about rare diseases and genetics as a “homeschooling mom without a degree” 37:54 Insights into how elements of spirituality can support advocacy work 40:18 Closing remarks Find out more Genetic Alliance (https://geneticalliance.org/) Please consider rating and reviewing us on your chosen podcast listening platform!  https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

    42 min

  6. MAR 13

    EP 178: Expanding the human proteome to facilitate drug discovery with John Lepore of ProFound Therapeutics

    This week on The Genetics Podcast, Patrick is joined by Dr. John Lepore, physician-scientist and CEO of ProFound Therapeutics. They discuss ProFound Tx’s mission to expand the proteome to identify novel drug targets – which resulted in the ProFoundry atlas – and the ways in which John’s diverse experiences inform his approach as a leader. Show Notes:  0:00 Intro to The Genetics Podcast 00:59 Welcome to John 02:01 John’s background at GSK and his transition to drug discovery 05:45 Establishing ProFound Therapeutics to expand the proteome and identify novel drug targets  08:27 Genomic origins of newly-identified proteins and the process of finding them 09:49 Developing the ProFoundry atlas and integrating data across assays  15:27 Different approaches to inferring protein links and association to disease 17:13 Collaboration with Pfizer to find regulators in the context of obesity 18:04 Developing novel antibody-drug conjugates for cancer treatment 20:27 Clarifying causality in proteomic data 21:59 Approaching novel targets while considering industrial and business factors 25:19 John’s background as a cardiologist and how that impacts his current work 27:26 Tips for biotech companies looking to be noticed by pharma for collaborations 30:30 Considerations for investigating new and different therapeutic modalities and techniques 33:39 How John consistently reinforces the translational angle as a business leader 36:24 Closing remarks and future direction for ProFound Therapeutics Find out more ProFound Therapeutics (https://www.profoundtx.com/) Please consider rating and reviewing us on your chosen podcast listening platform!  https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

    40 min

  7. MAR 6

    EP 177: The vision of Our Future Health with Raghib Ali

    This week on The Genetics Podcast, Patrick is joined by Raghib Ali, CEO, CMO, and Principal Investigator of Our Future Health UK. As a clinical epidemiologist with a passion for reducing health inequalities, Raghib offers fresh insights into the priorities, challenges, and transformative impact of the groundbreaking genomics initiative, Our Future Health.  Show Notes:  0:00 Intro to The Genetics Podcast 01:00 Welcome to Raghib and background on Our Future Health (OFH) 03:57 Diseases that are a priority for OFH or are likely to benefit from its impact 06:07 Challenges and opportunities for implementing change in the National Health Service (NHS), a partner of OFH, based on study findings 09:20 Factors that contributed to the rapid recruitment of participants to OFH 14:12 Efforts to ensure diversity of OFH participants and facilitate accessibility for all 16:35 Why OFH chose to use arrays for genomic profiling 18:57 Navigating the obstacles and opportunities in public and private partners 22:28 Strengths and weaknesses of the medical record system in the UK   25:54 Efforts to rapidly provide results from OFH and integrating other datasets and techniques in the future 28:43 Raghib’s unique educational and training journey  31:49 The importance of evaluating components beyond genetics for a full picture of health 33:28 Aims and findings of the first prospective cohort study in the UAE 35:26 The potential contribution of epigenetic inheritance to disease risk  37:43 How Raghib overcame adversity early in life 40:56 Closing remarks  Find out more Our Future Health (https://ourfuturehealth.org.uk/) Please consider rating and reviewing us on your chosen podcast listening platform!  https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

    43 min

  8. FEB 27

    EP 176: Hunting rare kidney disease mutations with Anthony Bleyer of Wake Forest and Stan Kmoch of Charles University

    This week on The Genetics Podcast, we’re celebrating Rare Disease Day with a very special episode. Patrick is joined by clinical nephrologist Anthony Bleyer and geneticist Stan Kmoch to discuss how their decade-long international collaboration has uncovered genetic mutations in families with rare inherited kidney diseases – including Patrick’s. Show Notes:  0:00 Intro to The Genetics Podcast 00:59 Welcome to Anthony and Stan 02:05 The origin story for Anthony and Stan’s long-distance collaboration 06:55 Stan’s background in metabolic disorders and sequencing techniques 11:09 Common genetic culprits and barriers to identifying mutations that cause kidney disease 14:01 Background and findings from Anthony and Stan’s ApoA4 study 23:54 Potential therapeutic avenues based on the ApoA4 study 26:49 Current and future focuses for characterizing diseases in families 30:42 Working with collaborators internationally to access large databases and registries 33:05 Innovative transplant methods, including genetically-modified pig kidneys   36:36 Closing remarks and a heartfelt thank you to researchers and families driving rare disease research Find out more Latest study: https://doi.org/10.1016/j.kint.2023.11.021 Please consider rating and reviewing us on your chosen podcast listening platform!  https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

    38 min
See All (183)

4.8
out of 5
43 Ratings

About

Exploring all things genetics. Dr Patrick Short, University of Cambridge alumnus and CEO of Sano Genetics, analyses the science, interviews the experts, and discusses the latest findings and breakthroughs in genetic research. To find out more about Sano Genetics and its mission to accelerate the future of precision medicine visit: www.sanogenetics.com

Information

  • Creator
    Sano Genetics
  • Years Active
    2019 - 2025
  • Episodes
    183
  • Rating
    Clean
  • Copyright
    © Sano Genetics
  • Show Website
    The Genetics Podcast

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada